• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃腺癌中超级增强子相关长链非编码RNA的免疫浸润与临床结局

Immune Infiltration and Clinical Outcome of Super-Enhancer-Associated lncRNAs in Stomach Adenocarcinoma.

作者信息

Peng Li, Peng Jiang-Yun, Cai Dian-Kui, Qiu Yun-Tan, Lan Qiu-Sheng, Luo Jie, Yang Bing, Xie Hai-Tao, Du Ze-Peng, Yuan Xiao-Qing, Liu Yue, Yin Dong

机构信息

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

出版信息

Front Oncol. 2022 Mar 3;12:780493. doi: 10.3389/fonc.2022.780493. eCollection 2022.

DOI:10.3389/fonc.2022.780493
PMID:35311149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8927879/
Abstract

Super-enhancers (SEs) comprise large clusters of enhancers that highly enhance gene expression. Long non-coding RNAs (lncRNAs) tend to be dysregulated in cases of stomach adenocarcinoma (STAD) and are vital for balancing tumor immunity. However, whether SE-associated lncRNAs play a role in the immune infiltration of STAD remains unknown. In the present study, we identified SE-associated lncRNAs in the H3K27ac ChIP-seq datasets from 11 tumor tissues and two cell lines. We found that the significantly dysregulated SE-associated lncRNAs were strongly correlated with immune cell infiltration through the application of six algorithms (ImmuncellAI, CIBERSORT, EPIC, quantiSeq, TIMER, and xCELL), as well as immunomodulators and chemokines. We found that the expression of SE-associated lncRNA TM4SF1-AS1 was negatively correlated with the proportion of CD8+ T cells present in STAD. TM4SF1-AS1 suppresses T cell-mediated immune killing function and predicts immune response to anti-PD1 therapy. ChIP-seq, Hi-C and luciferase assay results verified that TM4SF1-AS1 was regulated by its super-enhancer. RNA-seq data showed that TM4SF1-AS1 is involved in immune and cancer-related processes or pathways. In conclusion, SE-associated lncRNAs are involved in the tumor immune microenvironment and act as indicators of clinical outcomes in STAD. This study highlights the importance of SE-associated lncRNAs in the immune regulation of STAD.

摘要

超级增强子(SEs)由大量高度增强基因表达的增强子簇组成。长链非编码RNA(lncRNAs)在胃腺癌(STAD)病例中往往失调,并且对平衡肿瘤免疫至关重要。然而,与SE相关的lncRNAs是否在STAD的免疫浸润中发挥作用仍不清楚。在本研究中,我们从11个肿瘤组织和两个细胞系的H3K27ac ChIP-seq数据集中鉴定出与SE相关的lncRNAs。通过应用六种算法(ImmuncellAI、CIBERSORT、EPIC、quantiSeq、TIMER和xCELL)以及免疫调节剂和趋化因子,我们发现显著失调的与SE相关的lncRNAs与免疫细胞浸润密切相关。我们发现与SE相关的lncRNA TM4SF1-AS1的表达与STAD中CD8+T细胞的比例呈负相关。TM4SF1-AS1抑制T细胞介导的免疫杀伤功能,并预测对抗PD1治疗的免疫反应。ChIP-seq、Hi-C和荧光素酶检测结果证实TM4SF1-AS1受其超级增强子调控。RNA-seq数据表明TM4SF1-AS1参与免疫和癌症相关的过程或途径。总之,与SE相关的lncRNAs参与肿瘤免疫微环境,并作为STAD临床结果的指标。本研究突出了与SE相关的lncRNAs在STAD免疫调节中的重要性。

相似文献

1
Immune Infiltration and Clinical Outcome of Super-Enhancer-Associated lncRNAs in Stomach Adenocarcinoma.胃腺癌中超级增强子相关长链非编码RNA的免疫浸润与临床结局
Front Oncol. 2022 Mar 3;12:780493. doi: 10.3389/fonc.2022.780493. eCollection 2022.
2
Differential Expression of Super-Enhancer-Associated Long Non-coding RNAs in Uterine Leiomyomas.子宫肌瘤中超增强子相关长非编码 RNA 的差异表达。
Reprod Sci. 2022 Oct;29(10):2960-2976. doi: 10.1007/s43032-022-00981-4. Epub 2022 May 31.
3
LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.长链非编码 RNA DSCAM-AS1 通过与 YBX1 相互作用形成正反馈环,激活 FOXA1 转录网络,从而促进癌症进展。
Theranostics. 2020 Aug 29;10(23):10823-10837. doi: 10.7150/thno.47830. eCollection 2020.
4
Screening lncRNAs with diagnostic and prognostic value for human stomach adenocarcinoma based on machine learning and mRNA-lncRNA co-expression network analysis.基于机器学习和 mRNA-lncRNA 共表达网络分析筛选具有人类胃腺癌诊断和预后价值的长非编码 RNA。
Mol Genet Genomic Med. 2020 Nov;8(11):e1512. doi: 10.1002/mgg3.1512. Epub 2020 Oct 1.
5
LncRNAs Target Ferroptosis-Related Genes and Impair Activation of CD4 T Cell in Gastric Cancer.长链非编码RNA靶向胃癌中与铁死亡相关的基因并损害CD4 T细胞的激活。
Front Cell Dev Biol. 2021 Dec 13;9:797339. doi: 10.3389/fcell.2021.797339. eCollection 2021.
6
Metabolism-related long non-coding RNA in the stomach cancer associated with 11 AMMLs predictive nomograms for OS in STAD.与11种急性髓系单核细胞白血病相关的胃癌中与代谢相关的长链非编码RNA用于胃腺癌总生存期的预测列线图
Front Genet. 2023 Mar 13;14:1127132. doi: 10.3389/fgene.2023.1127132. eCollection 2023.
7
Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability.胃腺癌中长链非编码RNA的表达模式可作为肿瘤突变负荷的指标,并与肿瘤浸润淋巴细胞和微卫星不稳定性相关。
Front Cell Dev Biol. 2021 Feb 12;9:618313. doi: 10.3389/fcell.2021.618313. eCollection 2021.
8
Identification of aberrantly expressed long non-coding RNAs in stomach adenocarcinoma.胃腺癌中异常表达的长链非编码RNA的鉴定
Oncotarget. 2017 Jul 25;8(30):49201-49216. doi: 10.18632/oncotarget.17329.
9
Super enhancer lncRNAs: a novel hallmark in cancer.超级增强子长链非编码 RNA:癌症的一个新标志。
Cell Commun Signal. 2024 Apr 2;22(1):207. doi: 10.1186/s12964-024-01599-6.
10
A New Strategy to Identify ceRNA-Based CCDC144NL-AS1/SERPINE1 Regulatory Axis as a Novel Prognostic Biomarker for Stomach Adenocarcinoma High Throughput Transcriptome Data Mining and Computational Verification.一种基于ceRNA的CCDC144NL-AS1/SERPINE1调控轴作为胃腺癌新的预后生物标志物的鉴定新策略:高通量转录组数据挖掘与计算验证
Front Oncol. 2022 Jan 27;11:802727. doi: 10.3389/fonc.2021.802727. eCollection 2021.

引用本文的文献

1
Super-enhancers in immune system regulation: mechanisms, pathological reprogramming, and therapeutic opportunities.免疫系统调节中的超级增强子:机制、病理重编程及治疗机会
Front Immunol. 2025 Aug 15;16:1652398. doi: 10.3389/fimmu.2025.1652398. eCollection 2025.
2
Mechanistic insights into super-enhancer-related genes as prognostic signatures in colon cancer.解析超增强子相关基因在结肠癌中作为预后标志物的机制见解。
Aging (Albany NY). 2024 Jun 7;16(11):9918-9932. doi: 10.18632/aging.205906.
3
Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer.

本文引用的文献

1
Effect and mechanism of downregulating the long-chain noncoding RNA TM4SF1-AS1 on the proliferation, apoptosis and invasion of gastric cancer cells.下调长链非编码 RNA TM4SF1-AS1 对胃癌细胞增殖、凋亡和侵袭的影响及其机制。
World J Surg Oncol. 2021 Jul 31;19(1):226. doi: 10.1186/s12957-021-02334-y.
2
HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression.HIF-1α 激活的 TM4SF1-AS1 通过增强 TM4SF1 的表达促进肝癌细胞的增殖、迁移和侵袭。
Biochem Biophys Res Commun. 2021 Aug 20;566:80-86. doi: 10.1016/j.bbrc.2021.06.011. Epub 2021 Jun 10.
3
超级增强子诱导的LINC00862的泛癌分析及其作为宫颈癌和胃癌中SIRT1促进因子的验证
Transl Oncol. 2024 Jul;45:101982. doi: 10.1016/j.tranon.2024.101982. Epub 2024 May 7.
4
Super enhancer lncRNAs: a novel hallmark in cancer.超级增强子长链非编码 RNA:癌症的一个新标志。
Cell Commun Signal. 2024 Apr 2;22(1):207. doi: 10.1186/s12964-024-01599-6.
5
Gastric Cancer in the Era of Epigenetics.《表观遗传学时代的胃癌》
Int J Mol Sci. 2024 Mar 16;25(6):3381. doi: 10.3390/ijms25063381.
6
Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status.超级增强子及其组成部分:从预测努力到特征状态。
Int J Mol Sci. 2024 Mar 7;25(6):3103. doi: 10.3390/ijms25063103.
7
Integrative analysis and risk model construction for super‑enhancer‑related immune genes in clear cell renal cell carcinoma.透明细胞肾细胞癌中超级增强子相关免疫基因的综合分析与风险模型构建
Oncol Lett. 2024 Mar 1;27(5):190. doi: 10.3892/ol.2024.14323. eCollection 2024 May.
8
Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy.长非编码 RNA 在癌症中的作用:多方面的角色和免疫治疗的潜在靶点。
Mol Cell Biochem. 2024 Dec;479(12):3229-3254. doi: 10.1007/s11010-024-04933-1. Epub 2024 Feb 28.
9
Effects of BRD4 inhibitor JQ1 on the expression profile of super-enhancer related lncRNAs and mRNAs in cervical cancer HeLa cells.BRD4 抑制剂 JQ1 对宫颈癌 HeLa 细胞中超增强子相关长链非编码 RNA 和信使 RNA 表达谱的影响。
PeerJ. 2024 Feb 23;12:e17035. doi: 10.7717/peerj.17035. eCollection 2024.
10
Differential roles of highly expressed PFKFB4 in colon adenocarcinoma patients.高表达的 PFKFB4 在结肠腺癌患者中的差异作用。
Sci Rep. 2023 Sep 28;13(1):16284. doi: 10.1038/s41598-023-43619-4.
Current treatment and recent progress in gastric cancer.
胃癌的当前治疗方法和最新进展。
CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Gene regulation by long non-coding RNAs and its biological functions.长非编码 RNA 的基因调控及其生物学功能。
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118. doi: 10.1038/s41580-020-00315-9. Epub 2020 Dec 22.
6
RNA in cancer.癌症中的 RNA。
Nat Rev Cancer. 2021 Jan;21(1):22-36. doi: 10.1038/s41568-020-00306-0. Epub 2020 Oct 20.
7
LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1.长链非编码RNA SNHG15通过靶向miR141/PD-L1促进胃癌的免疫逃逸。
Onco Targets Ther. 2020 Aug 24;13:8547-8556. doi: 10.2147/OTT.S251625. eCollection 2020.
8
lncRNA TM4SF1-AS1 Activates the PI3K/AKT Signaling Pathway and Promotes the Migration and Invasion of Lung Cancer Cells.长链非编码RNA TM4SF1-AS1激活PI3K/AKT信号通路并促进肺癌细胞的迁移和侵袭。
Cancer Manag Res. 2020 Jul 7;12:5527-5536. doi: 10.2147/CMAR.S254072. eCollection 2020.
9
LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.长链非编码 RNA GATA3-AS1 通过稳定 PD-L1 并破坏 GATA3 促进三阴性乳腺癌的肿瘤进展和免疫逃逸。
Cell Prolif. 2020 Sep;53(9):e12855. doi: 10.1111/cpr.12855. Epub 2020 Jul 20.
10
Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Biomarker for Early Detection and Monitoring Progression of Gastric Cancer: A Multiphase Study.循环外泌体胃癌相关长非编码 RNA1 作为胃癌早期检测和监测进展的生物标志物:一项多阶段研究。
JAMA Surg. 2020 Jul 1;155(7):572-579. doi: 10.1001/jamasurg.2020.1133.